COMBINED MODALITY TREATMENT WITH INTENSIFIED CHEMOTHERAPY AND DOSE-REDUCED INVOLVED FIELD RADIOTHERAPY IN PATIENTS WITH EARLY UNFAVOURABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD11 TRIAL

被引：0
|
作者：
Engert, A.
Borchmann, P.
Diehl, V. [1 ]
Goergen, H. [1 ]
Mueller, H. [1 ]
Mueller, R.
Eich, H.
Mueller-Hermelink, H. [2 ]
Herrmann, R. [3 ]
Markova, J. [4 ]
Ho, A. [5 ]
Hiddemann, W. [6 ]
Doerken, B. [7 ]
Greil, R. [8 ]
机构：
[1] Univ Hosp Cologne, CHSG, Cologne, Germany
[2] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[3] Kantonsspital Basel, Basel, Switzerland
[4] Univ Hosp Prague, Prague, Czech Republic
[5] Heidelberg Univ, Med Clin V, Heidelberg, Germany
[6] Univ Hosp Grosshadern, Munich, Germany
[7] Charite, D-13353 Berlin, Germany
[8] Salzburg Univ, A-5020 Salzburg, Austria
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0410
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [41] Leucopenia during treatment is a good prognostic risk factor for patients undergoing chemotherapy for Hodgkin's lymphoma: An analysis of the German Hodgkin study group (GHSG).
    Klimm, B
    Reineke, T
    Haverkamp, H
    Eich, HT
    Behringer, K
    Josting, A
    Pfistner, B
    Diehl, V
    Engert, A
    BLOOD, 2005, 106 (11) : 750A - 751A
  • [42] Intensification of chemotherapy and concomitant reduction of radiotherapy dose in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD 11 trial of the GHSG.
    Diehl, V
    Brillant, C
    Engert, A
    Wolf, J
    Nogova, L
    Mueller, RP
    Eich, H
    Hermelink, HKM
    Herrman, R
    Markova, J
    Ho, A
    Hiddemann, W
    Doerken, B
    Greil, R
    Pfistner, B
    BLOOD, 2004, 104 (11) : 368A - 368A
  • [43] Comparison between the Involved Field Radiotherapy of the German Hodgkin Study Group (GHSG) and the Involved Site Radiotherapy (IS-RT) of the International Lymphoma Radiation Oncology Group (ILROG) Involved Site Radio Therapy (IS-RT) in Patients with Hodgkin Lymphoma
    Kriz, J.
    Haverkamp, U.
    Frick, S.
    Eich, H. -T
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 13 - 13
  • [44] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG)
    Diehl, V.
    Haverkamp, H.
    Mueller, R.
    Mueller-Hermelink, H.
    Cerny, T.
    Markova, J.
    Ho, A. D.
    Kanz, L.
    Greil, R.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE HODGKIN LYMPHOMA (HL): UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7, HD8, HD10 AND HD11 TRIALS
    Broeckelmann, P. J.
    Goergen, H.
    Pluetschow, A.
    Kreissl, S.
    Buerkle, C.
    Borchmann, S.
    Fuchs, M.
    Borchmann, P.
    Engert, A.
    HAEMATOLOGICA, 2016, 101 : 4 - 4
  • [46] FDG-PET for assessment of residual tissue after completion of chemotherapy in advance stage Hodgkin lymphoma - Report on the final analysis of the PET investigation in the trial HD15 of the German Hodgkin Study Group (GHSG)
    Kobe, Carsten
    Haverkamp, Heinz
    Hans, Eich
    Markova, Jana
    Dietlein, Markus
    Engert, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [47] Involved-field (IF) Versus Extended-field (EF) Radiation Therapy (RT) for Patients in Early Unfavorable Stages of Hodgkin Lymphoma: 10-year Update of the HD8 Trial of the German Hodgkin Study Group (GHSG)
    Eich, H. T.
    Kriz, J.
    Klimm, B.
    Sasse, S.
    Goergen, H.
    Diehl, V.
    Borchmann, P.
    Mueller, R.
    Engert, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S70 - S70
  • [48] Quality Control of Involved Field (IF)-radiotherapy for Patients with Early-stage Hodgkin Lymphoma Based on a Central Prospective Review: Comparison of the Results between Two Study Generations of the German Hodgkin Study Group (GHSG)
    Kriz, J.
    Mueller, R. P.
    Bangard, C.
    Bongartz, R.
    Engert, A.
    Eich, H. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S543 - S544
  • [49] Quality control of the involved field (IF)-radiotherapy for patients with early-stage Hodgkin lymphoma based on a central prospective review comparison of the results between two study generations of the German Hodgkin Study Group (GHSG)
    Eich, H. T.
    Kriz, J.
    Bangard, C.
    Bongartz, R.
    Engert, A.
    Mueller, R. -P.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 76 - 76
  • [50] Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial
    Behringer, K.
    Thielen, I.
    Mueller, H.
    Goergen, H.
    Eibl, A. D.
    Rosenbrock, J.
    Halbsguth, T.
    Eichenauer, D. A.
    Fuchs, M.
    Reiners, K. S.
    Renno, J. H.
    van der Ven, K.
    Kuehr, M.
    von Wolff, M.
    Diehl, V.
    Engert, A.
    Borchmann, P.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1818 - 1825
12345